Benjamin Cherry, MD, FACP
Assistant Professor of Medicine (General Medicine); Director, Internal Medicine Subinternship
Research & Publications
Biography
News
Research Summary
Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study
National Cancer Institute Clinical Trial #NCT01675141
- Multiple myeloma is rarely curable, but it is treatable. Initial treatment is directed at controlling symptoms and reducing the number of myeloma cells. It continues until the cancer stops responding to treatment. At that time, treatment may switch to maintenance therapy, which is given to try to extend the response of the first therapy for as long as possible. Research suggests that lenalidomide maintenance therapy may delay the time for myeloma cells to start to grow and possibly improve survival.
- Lenalidomide is a drug that may reduce or prevent the growth of cancer cells. This study examines the long-term effect of lenalidomide on immune cells. It will also look at the effects of extended treatment on the cancer and the immune system.
Coauthors
Research Interests
Curriculum; Health Policy; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Paraproteinemias; Lung Diseases, Interstitial; Hematologic Neoplasms; Idiopathic Pulmonary Fibrosis; Quality Improvement
Selected Publications
- Prevalence of harmful diagnostic errors in hospitalised adults: a systematic review and meta-analysisGunderson CG, Bilan VP, Holleck JL, Nickerson P, Cherry BM, Chui P, Bastian LA, Grimshaw AA, Rodwin BA. Prevalence of harmful diagnostic errors in hospitalised adults: a systematic review and meta-analysis. BMJ Quality & Safety 2020, 29: 1008-1018. PMID: 32269070, DOI: 10.1136/bmjqs-2019-010822.
- Do Patients with Cellulitis Need to be Hospitalized? A Systematic Review and Meta-analysis of Mortality Rates of Inpatients with CellulitisGunderson CG, Cherry BM, Fisher A. Do Patients with Cellulitis Need to be Hospitalized? A Systematic Review and Meta-analysis of Mortality Rates of Inpatients with Cellulitis. Journal Of General Internal Medicine 2018, 33: 1553-1560. PMID: 30022408, PMCID: PMC6108983, DOI: 10.1007/s11606-018-4546-z.
- S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertensionTzouvelekis A, Herazo‐Maya J, Ryu C, Chu J, Zhang Y, Gibson KF, Adonteng‐Boateng P, Li Q, Pan H, Cherry B, Ahmad F, Ford HJ, Herzog EL, Kaminski N, Fares WH. S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension. Respirology 2018, 23: 771-779. PMID: 29611244, PMCID: PMC6047907, DOI: 10.1111/resp.13302.
- Integrating Behavioral Health and Primary CareKatz R, Cherry B. Integrating Behavioral Health and Primary Care. American Journal Of Psychiatry 2017, 174: 1125-1125. DOI: 10.1176/appi.ajp.2017.17080927.
- Peer-Assisted Learning in Introductory Histopathology Improves Learner Scores and Delivers Learner SatisfactionBeck A, Wood C, Helms R, Arvizo C, Cherry B, Ziats N. Peer-Assisted Learning in Introductory Histopathology Improves Learner Scores and Delivers Learner Satisfaction. Medical Science Educator 2015, 26: 85-92. DOI: 10.1007/s40670-015-0207-6.
- Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Maric I, Calvo KR, Braylan R, Stetler-Stevenson M, Yuan C, Tembhare P, Zingone A, Costello R, Roschewski MJ, Landgren O. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leukemia & Lymphoma 2013, 54: 2215-8. PMID: 23311294, PMCID: PMC7561256, DOI: 10.3109/10428194.2013.764419.
- Evolving therapeutic paradigms for multiple myeloma: back to the future.Cherry BM, Korde N, Kwok M, Roschewski M, Landgren O. Evolving therapeutic paradigms for multiple myeloma: back to the future. Leukemia & Lymphoma 2013, 54: 451-63. PMID: 22880935, DOI: 10.3109/10428194.2012.717277.
- Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age.Cherry BM, Costello R, Zingone A, Burris J, Korde N, Manasanch E, Kwok M, Annunziata C, Roschewski MJ, Engels EA, Landgren O. Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age. American Journal Of Hematology 2013, 88: 89-92. PMID: 23169485, PMCID: PMC5572208, DOI: 10.1002/ajh.23355.